What factors drove the changes in Amgen's revenue and profit?

Did Amgen beat or miss consensus estimates last quarter?

What guidance did Amgen's management provide for the next earnings period?

What is the market's earnings forecast for Amgen next quarter?

What is the revenue and EPS growth rate for Amgen year over year?

What is Amgen's gross profit margin?

What is Amgen's latest dividend and current dividend yield?

What were the key takeaways from Amgen’s earnings call?

- **Revenue Growth**: 10% full-year growth, driven by Repatha (36%), EVENITY (34%), and rare disease portfolio ($5.2B).
- **Pipeline Breakthroughs**: MariTide Phase III expansion, Repatha's VESALIUS-CV cardiovascular data, and UPLIZNA's gMG approval.
- **Financial Strength**: $8.1B free cash flow, 2026 guidance for $30.8B-$31.8B revenue, and $21.60-$23.00 EPS.
- **Strategic Initiatives**: MariTide launch preparation, AmgenNow program, and biosimilar expansion.

**【CEO Summary Section】**
- **2025 Performance Highlights**: 14 blockbuster products, 13 with double-digit growth, and 18 record sales. Key growth drivers include Repatha (36% growth), EVENITY (34%), TEZSPIRE (52%), rare disease, oncology, and biosimilars.
- **Pipeline Momentum**: MariTide advancing in obesity, type 2 diabetes, and ASCVD; olpasiran targeting Lp(a) reduction; Repatha's VESALIUS-CV trial showing 25% risk reduction in cardiovascular events.

**【R&D Update】**
- **MariTide Progress**: Six Phase III studies underway, including sleep apnea and type 2 diabetes. Phase II data supports monthly/bimonthly dosing efficacy.
- **Repatha Landmark Data**: VESALIUS-CV trial demonstrates 25% relative risk reduction in first cardiovascular events, reinforcing leadership in LDL-C lowering.
- **UPLIZNA Expansion**: FDA approval for generalized myasthenia gravis; Phase III studies in autoimmune hepatitis and CIDP initiated.
- **Oncology Breakthroughs**: IMDELLTRA granted full FDA approval for small cell lung cancer; xaluritamig advancing in prostate cancer.

**【Commercial Update】**
- **Top Performers**: Repatha ($3B+ sales), EVENITY ($2.1B), TEZSPIRE ($1.5B), and rare disease portfolio ($5.2B). UPLIZNA grew 73% to $655M.
- **Market Access Innovations**: AmgenNow direct-to-patient program; expansion into generics (TrumpRx) to enhance affordability.
- **Biosimilars Growth**: $3B in 2025, driven by PAVBLU ($700M) and next-wave launches.

**【CFO Financial Commentary】**
- **2025 Financials**: Non-GAAP operating margin 46%, R&D spend $7.2B, free cash flow $8.1B.
- **2026 Guidance**: Revenue $30.8B-$31.8B, EPS $21.60-$23.00. Q1 seasonal headwinds expected, with MariTide launch preparation.
- **Capital Allocation**: $2.6B capex for manufacturing expansion; $3B share buybacks.

**【Q&A Highlights】**
- **MariTide Dosing**: Potential for quarterly dosing post-weight goal; Phase III design for type 2 diabetes CVOT under discussion.
- **Repatha Competition**: Confident in data-driven growth despite oral PCSK9 entrants.
- **TAVNEOS Regulatory Update**: FDA requested re-adjudication of 9 patients; ongoing discussions to resolve discrepancies.
- **Biosimilar Strategy**: PAVBLU leading EYLEA biosimilar market; prepared for competitive launches.


Amgen Inc. (AMGN) Q4 2025 Earnings Call Transcript

- **Revenue Growth**: Q3 2025 revenue up 12% YoY to $9.6B, driven by 14% volume growth across all therapeutic areas.
- **Pipeline Momentum**: Repatha sales +40% YoY to $794M; EVENITY +36% YoY to $541M; MariTide Phase III trials fully enrolled.
- **Strategic Initiatives**: $3B+ manufacturing investments; AmgenNow program offers Repatha at $239/month; 2025 guidance raised for revenue and EPS.
- **Key Clinical Updates**: Repatha VESALIUS-CV study shows 25% MACE risk reduction; IMDELLTRA Phase III data submission with 81% 2-year OS in frontline setting.
- **Financial Strength**: 47% operating margin; $4.2B free cash flow; $2.38/share dividend (6% increase).

**【CEO Summary Section】**
- Delivered strong Q3 2025 results with 12% YoY revenue growth ($9.6B) driven by volume growth across all therapeutic areas.
- Highlighted Repatha's 40% YoY sales growth to $794M and EVENITY's 36% YoY growth to $541M, reflecting pipeline momentum.
- Emphasized manufacturing investments ($3B+ in 2025) and strategic focus on rare diseases (UPLIZNA) and oncology (IMDELLTRA).
- Launched AmgenNow, offering Repatha at $239/month, targeting 100M+ patients with unmet cardiovascular needs.

**【CFO Financial Commentary】**
- Non-GAAP operating margin of 47% supported by $4.2B free cash flow and $2.38/share dividend (6% increase).
- R&D expenses up 31% YoY to $1.4B, driven by late-stage pipeline investments (MariTide, Olpasiran).
- Raised 2025 guidance: Revenue $35.8-36.6B vs. prior $35.3-36.1B; Non-GAAP EPS $20.60-21.40 vs. prior $20.30-21.10.
- Capital allocation focused on innovation, with $2.2-2.3B in capex for pipeline expansion.

**【Q&A Highlights】**
- **Repatha VESALIUS-CV Study**: Demonstrated 25% relative risk reduction in MACE in primary prevention; data to be presented at AHA 2025.
- **Biosimilars Strategy**: AMGEVITA (adalimumab biosimilar) on track for $3B+ annualized sales; PAVBLU (EYLEA biosimilar) gaining momentum.
- **MariTide Obesity Program**: Phase II Part 2 maintenance study shows durable weight loss; Phase III trials fully enrolled with 5,000+ patients.
- **Olpasiran (Lp(a) inhibitor)**: OCEAN(a) Phase III cardiovascular outcomes study progressing despite lower-than-expected event rate; confident in best-in-class profile.
- **IMDELLTRA (small cell lung cancer)**: Phase III data submission with PDUFA date December 18, 2025; frontline maintenance study showing 81% 2-year OS.


Amgen Inc. (AMGN) Q3 2025 Earnings Call Transcript

- **Revenue & Growth**: Q2 2025 revenue of $9.2B (+9% YoY), driven by 13% volume growth. 15 products achieved double-digit sales growth.
- **Pipeline Breakthroughs**: IMDELLTRA shows 40% reduction in death risk in small cell lung cancer. MariTide Phase III studies targeting cardiovascular outcomes.
- **Financial Strength**: Non-GAAP EPS guidance of $20.20-$21.30, with $1.9B free cash flow in Q2. R&D spend up 18% YoY to $1.7B.
- **Strategic Initiatives**: AI integration across R&D. Biosimilar portfolio generates $661M in Q2 (+40% YoY). MariTide poised for broad obesity-related indications.


**【CEO Summary Section】**
- **Revenue Growth**: Q2 2025 revenue of $9.2 billion, up 9% YoY, driven by 13% volume growth. 15 products achieved double-digit sales growth.
- **Strategic Focus**: Emphasized AI integration across R&D and commercial operations. Highlighted MariTide (obesity) and IMDELLTRA (small cell lung cancer) as key growth drivers.
- **Pipeline Momentum**: 4 Phase III studies for MariTide underway, with cardiovascular outcomes trials (MARITIME-CV, MARITIME-HF) and obstructive sleep apnea trials expected to initiate this year.

**【CFO Financial Commentary】**
- **Financial Performance**: Non-GAAP EPS of $20.20-$21.30 for 2025, with free cash flow of $1.9 billion in Q2. R&D spend increased 18% YoY to $1.7 billion, driven by late-stage pipeline investments.
- **Guidance**: Full-year revenue target of $35.0-$36.0 billion. Non-GAAP operating margin expected at ~45%, reflecting $200 million incremental R&D expenses from business development deals.
- **Capital Allocation**: Returned $2.38 billion to shareholders via dividends (6% increase). Biosimilar portfolio generated $661 million in Q2, up 40% YoY.

**【Commercial Progress】**
- **General Medicine**: Repatha ($696M, +31% YoY) and EVENITY ($518M, +32% YoY) led growth. MariTide Phase III enrollment strong across geographies.
- **Rare Disease**: TEPEZZA ($505M, +5% YoY) and UPLIZNA ($176M, +91% YoY) drove $1.4 billion in rare disease sales. UPLIZNA expanded into IgG4-related disease and myasthenia gravis.
- **Inflammation/Oncology**: TEZSPIRE ($342M, +46% YoY) and IMDELLTRA ($134M) showed strong adoption. IMDELLTRA achieved 5-month OS improvement vs. chemotherapy in Phase III.

**【R&D Pipeline Updates】**
- **Obesity**: MariTide Phase III studies (MARITIME-CV, MARITIME-HF) evaluate cardiovascular benefits. 89% remission rates in Phase Ib/II subcutaneous blinatumomab trials.
- **Oncology**: IMDELLTRA Phase III data showed 40% reduction in death risk. Xaluritamig Phase Ib studies ongoing for prostate cancer.
- **Cardiovascular**: Repatha VESALIUS-CVOT expected late 2025. Olpasiran Phase III OCEAN(a) trial maturing for Lp(a) reduction.

**【Q&A Highlights】**
- **MariTide Strategy**: Phase III design includes 3-step dose escalation for tolerability. Q4 2025 data will include 52-week weight loss and maintenance insights.
- **Policy & Pricing**: Engaged with government on drug pricing reforms, balancing affordability with innovation. Biosimilar portfolio remains competitive with 100% regulatory success rate.
- **Rare Disease Expansion**: Open to M&A but focused on organic growth. TEPEZZA subcutaneous formulation Phase III enrollment complete.
- **IMDELLTRA Momentum**: 50% of doses administered in community settings. Phase III studies evaluating earlier lines of therapy and subcutaneous delivery.


Amgen Inc. (AMGN) Q2 2025 Earnings Call Transcript

- **Revenue Growth**: $8.1 billion (+9% YoY), driven by 14% volume growth in core products.
- **Key Product Wins**: Repatha (+27%), EVENITY (+29%), IMDELLTRA ($81M Q1 sales), UPLIZNA IgG4 approval.
- **Pipeline Momentum**: MariTide Phase III enrollment, IMDELLTRA Phase III OS data, BLINCYTO subcutaneous BTD.
- **Financial Discipline**: 45.7% operating margin, $1B free cash flow, $2.3B capex for growth.
- **Strategic Focus**: Biosimilars (+35% YoY), rare disease expansion, oncology innovation.


**【CEO Opening Remarks】**
- Q1 2025 revenue reached $8.1 billion, up 9% YoY, driven by 14% volume growth across key products like Repatha, BLINCYTO, TEZSPIRE, and EVENITY.
- 14 medicines delivered double-digit sales growth, including Repatha (+27%), EVENITY (+29%), and UPLIZNA (+14%).
- New product launches (PAVBLU, WEZLANA, BEKEMV) and Phase III data in oncology (IMDELLTRA) and rare diseases (UPLIZNA for IgG4) highlight strategic momentum.
- Reaffirmed 2025 guidance: $34.3-35.7 billion in revenue and $20-21.20 non-GAAP EPS.

**【CFO Financial Highlights】**
- Non-GAAP operating margin of 45.7%, up from prior outlook, due to delayed R&D spending.
- Free cash flow of $1.0 billion, with $2.3 billion in capital expenditures for manufacturing expansion.
- Returned $2.38 billion to shareholders via dividends, up 6% YoY.
- Expect R&D expenses to grow ~20% in 2025, driven by late-stage pipeline investments (MariTide, Olpasiran).

**【Key Product Updates】**
- **Repatha**: U.S. sales +26% YoY, 90% of primary care prescribers now activated.
- **EVENITY**: U.S. sales +36% YoY, targeting 2.5 million at-risk women.
- **IMDELLTRA**: $81 million in Q1 sales, Phase III data shows 31% improvement in overall survival vs. chemo.
- **UPLIZNA**: FDA-approved for IgG4-related disease, Phase III data in myasthenia gravis pending PDUFA in Dec 2025.
- **Biosimilars**: $735 million in Q1 sales (+35% YoY), PAVBLU U.S. launch surpasses expectations.

**【Pipeline Progress】**
- **MariTide**: 2 Phase III studies enrolling for chronic weight management, targeting 72-week data.
- **Olpasiran**: Phase III cardiovascular outcomes trial (OCEAN(a)) progressing for Lp(a) reduction.
- **IMDELLTRA**: Expansion into first-line small cell lung cancer with Phase III trial planned.
- **BLINCYTO**: Subcutaneous formulation granted Breakthrough Therapy Designation for relapsed/refractory ALL.

**【Q&A Highlights】**
- **Obesity Market**: MariTide's monthly dosing and cardiometabolic benefits position it to compete with oral GLP-1s.
- **UPLIZNA Commercialization**: Targeting 20,000 IgG4 patients in the U.S., with 85% of payers removing prior auth requirements.
- **Tariffs & Manufacturing**: $2 billion in U.S. manufacturing investments (Ohio, NC) to mitigate policy risks.
- **TEPEZZA Growth**: Global expansion (Japan, EU) and subcutaneous formulation in development to drive uptake.


Amgen (AMGN)-1 May 25-2025 Q1 Earnings call transcript

- **Revenue growth outperforms expectations**: 19% YoY increase to $33.4 billion, driven by 23% volume growth across 21 products.
- **Repatha and EVENITY lead the charge**: Repatha (+36%) and EVENITY (+35%) demonstrate strong clinical adoption, with biosimilar price erosion slowing in 2025.
- **Pipeline innovation accelerates**: MariTide Phase II data highlight sustained weight loss benefits, with Phase III trials set to begin in 2025. IMDELLTRA generates $115M in 7 months, positioning for broader oncology growth.
- **Biosimilars deliver returns**: $2.2 billion in 2024, with PAVBLU and WEZLANA launches driving 16% YoY growth. 2025 launches of new biosimilars to maintain momentum.
- **China oncology expansion**: Collaboration with BeiGene drives KYPROLIS and BLINCYTO adoption, with affiliate business growing on national reimbursement list.

**【CEO Summary Section】**
- 2024 marked another year of strong execution, with 14 products annualizing at over $1 billion in sales. Key growth drivers include Repatha (+36%), EVENITY (+35%), and oncology portfolio (+11%).
- Pipeline momentum includes Phase III data readouts for MariTide, olpasiran, and IMDELLTRA, with 2025 expected to be a milestone year for innovation across general medicine, rare disease, and oncology.
- Emphasis on AI adoption to accelerate drug discovery and commercial operations, supporting long-term growth through 2030.

**【Commercial Performance (Murdo Gordon)】**
- Full-year product sales grew 19% to $33.4 billion, driven by 23% volume growth. 10 products achieved double-digit growth, including Repatha (+36% to $2.2B), EVENITY (+35% to $1.6B), and oncology portfolio (+11% to $8B).
- Repatha expanded access globally, with U.S. prescribers up 50% and biosimilar price erosion expected to slow in 2025. EVENITY penetrated only 2% of high-risk patients, with significant growth potential.
- Rare disease portfolio (TEPEZZA, UPLIZNA) generated $4.5 billion, with TEPEZZA set to launch in 7 new markets in 2025. Biosimilars grew 16% to $2.2 billion, with PAVBLU and WEZLANA driving momentum.

**【R&D Pipeline Update (James Bradner)】**
- MariTide Phase II data show sustained weight loss and cardiometabolic benefits, with Phase III trials expected to begin in H1 2025. Olpasiran's Phase III cardiovascular outcomes trial (OCEAN(a)) is fully enrolled, targeting Lp(a)-elevated patients.
- UPLIZNA poised for approvals in IgG4-related disease and generalized myasthenia gravis, with 52-week data expected in 2025. IMDELLTRA generated $115M in 7 months post-launch, with Phase III data in extensive-stage SCLC expected in H1 2025.

**【Financial Highlights (Peter Griffith)】**
- 2024 revenue: $33.4 billion (+19% YoY), driven by 21 products with record sales. Non-GAAP EPS: $20.60, exceeding expectations. Free cash flow: $10.4 billion, supporting shareholder returns (dividend +6% YoY).
- 2025 guidance: Revenue $34.3B-$35.7B, EPS $20-$21.20. Operating margin ~46%, with R&D spend growing mid-teens to support pipeline. Free cash flow expected similar to 2023, reflecting capital allocation priorities.

**【Q&A Highlights】**
- **Repatha competition**: Management confident in Repatha's clinical benefit and access improvements, with VESALIUS-CV data expected H2 2024. Biosimilar price erosion for Repatha to slow to mid-single digits in 2025.
- **Biosimilar sustainability**: PAVBLU and WEZLANA launches demonstrate strong execution, with biosimilars expected to remain a key growth driver. 2025 launches of BEKEMV and others to expand portfolio.
- **MariTide strategy**: Phase III trials will focus on chronic weight management and cardiometabolic indications, with data expected in 2026. No head-to-head trials planned with incumbents.
- **China oncology growth**: Collaboration with BeiGene (BeOne) driving KYPROLIS, BLINCYTO, and XGEVA adoption. Amgen affiliate business growing with Repatha and Prolia on national reimbursement list.

Actual																	4.17	4.25	4.37	3.81	3.7	4.38	4.67	4.36	4.25	4.65	4.7	4.09	3.98	5	4.96	4.71	3.96	4.97	5.58	5.31	4.9	6.02	5.64	5.29
Forecast																	3.7399	3.8221	3.9263	3.3553	4.0479	4.0885	4.2949	4.0356	4.0953	4.4326	4.4667	4.0968	3.8473	4.4926	4.6691	4.5914	3.879	4.9847	5.2744	5.0906	4.2697	5.2814	5.019	4.7344
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+11.50%	+11.20%	+11.30%	+13.55%	-8.59%	+7.13%	+8.73%	+8.04%	+3.78%	+4.90%	+5.22%	-0.17%	+3.45%	+11.29%	+6.23%	+2.58%	+2.09%	-0.29%	+5.79%	+4.31%	+14.76%	+13.98%	+12.37%	+11.74%

Actual	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	6.16B	6.21B	6.42B	6.63B	5.90B	6.53B	6.71B	6.85B	6.24B	6.59B	6.65B	6.84B	6.11B	6.99B	6.90B	8.20B	7.45B	8.39B	8.50B	9.09B	8.15B	9.18B	9.56B	9.87B
Forecast	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	6.00B	6.19B	6.39B	6.57B	6.26B	6.46B	6.67B	6.87B	6.07B	6.53B	6.56B	6.74B	6.15B	6.66B	6.93B	8.13B	7.45B	8.35B	8.50B	8.88B	8.06B	8.94B	8.97B	9.47B
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+2.70%	+0.18%	+0.55%	+0.92%	-5.76%	+1.06%	+0.57%	-0.34%	+2.78%	+0.96%	+1.34%	+1.41%	-0.80%	+4.84%	-0.33%	+0.86%	-0.06%	+0.43%	+0.06%	+2.31%	+1.14%	+2.72%	+6.59%	+4.18%

AMGN

AMGN fundamentals

AMGN Q4 2025 Earnings

Earnings Call

You can ask Aime

AMGN

AMGN fundamentals

AMGN Q4 2025 Earnings

Earnings Call

AMGN Earnings Call Summary for Q4/20254:30 PM on Feb 3, 2026

AMGN Earnings Call Summary for Q3/20254:30 PM on Nov 4, 2025

AMGN Earnings Call Summary for Q2/20254:30 PM on Aug 5, 2025

AMGN Earnings Call Summary for Q1/20254:30 PM on May 1, 2025

AMGN Earnings Call Summary for Q4/20244:30 PM on Feb 4, 2025

You can ask Aime